Cimzia® (certolizumab pegol)
Through pooled data from the Cimzia arms of the
CIMPASI 1 and CIMPASI 2 trials.2
Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.13 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.14
Help us to grow our resource the way you want it to grow.